Ascendiant Capital Markets Lowers Aemetis (NASDAQ:AMTX) Price Target to $19.00

Aemetis (NASDAQ:AMTX) had its target price lowered by equities researchers at Ascendiant Capital Markets from $20.00 to $19.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the specialty chemicals company’s stock.

Several other brokerages have also commented on AMTX. StockNews.com upgraded Aemetis to a “sell” rating in a research report on Wednesday, July 31st. HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of Aemetis in a research note on Friday, August 2nd. UBS Group dropped their target price on shares of Aemetis from $8.25 to $7.75 and set a “buy” rating on the stock in a research report on Monday, August 19th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $3.50 price target (down from $4.00) on shares of Aemetis in a research note on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.95.

Aemetis Stock Performance

Shares of NASDAQ AMTX opened at $2.26 on Tuesday. The stock has a market capitalization of $100.34 million, a P/E ratio of -1.93 and a beta of 1.31. The stock’s fifty day moving average is $2.96 and its 200 day moving average is $3.55. Aemetis has a 52 week low of $2.10 and a 52 week high of $7.03.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings data on Thursday, August 1st. The specialty chemicals company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.25). The company had revenue of $66.56 million during the quarter, compared to analyst estimates of $75.37 million. During the same quarter in the previous year, the business earned ($0.68) earnings per share. Equities research analysts forecast that Aemetis will post -2.19 earnings per share for the current year.

Hedge Funds Weigh In On Aemetis

Institutional investors have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of Aemetis in the 1st quarter valued at about $60,000. Hutchinson Capital Management CA purchased a new stake in shares of Aemetis during the second quarter valued at approximately $70,000. State Board of Administration of Florida Retirement System bought a new position in shares of Aemetis in the first quarter worth approximately $84,000. Rhumbline Advisers grew its holdings in shares of Aemetis by 2,837.1% in the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock worth $157,000 after purchasing an additional 50,528 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Aemetis in the second quarter worth $306,000. 27.02% of the stock is currently owned by institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.